Menlo Park, California-based Orca Bio, a developer of high precision allogeneic cell therapies, has raised $192 million in Series D financing. The investors included Lightspeed Venture Partners, 8VC, DCVC Bio, ND Capital, Mubadala Investment Company, Kaiser Foundation Hospitals, Kaiser Permanente Group Trust and IMRF.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: